This trial will study whether the Fasting Mimicking diet can help improve the effectiveness of tofacitinib or ustekinumab therapy in people with ulcerative colitis, by measuring clinical response and changes in fecal calprotectin and C-reactive protein levels.
1 Primary · 2 Secondary · Reporting Duration: 8 weeks
76 Total Participants · 6 Treatment Groups
Primary Treatment: Fast Mimicking Diet · No Placebo Group · Phase 3
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Did not meet criteria||100.0%|